International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
The diagnostic value of hepatitis B core-related antigen in occult hepatitis B virus infection and its related hepatocellular carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhan Fuguo, Lin Caorui, Wu Xiufeng, Xun Zhen, Fu Ya, Chen Tianbin, Xu Siyi, Liu Can, Ou Qishui, Zhang Jiawei
Аннотация
OBJECTIVES: Occult hepatitis B virus (HBV) infection (OBI) has come to the fore recently. The study aimed to evaluate the value of serum hepatitis B core-related antigen (HBcrAg) in diagnosing OBI in hepatitis B surface antigen (HBsAg)-negative population, and the risk of OBI-related hepatocellular carcinoma (HCC) tumorigenesis, metastasis, and recurrence after radical surgery.
DESIGN AND METHODS: The OBI status was determined by nested polymerase chain reaction. HBcrAg and common HBV clinical indicators were compared between the OBI and non-OBI groups. A detection pathway based on HBcrAg was established for OBI diagnosis. HBsAg-negative patients (124 HCC and 53 non-HCC) were enrolled for risk assessment of HBcrAg in OBI-related HCC.
RESULTS: A detection pathway for diagnosing OBI based on HBcrAg combined with hypersensitive HBV DNA and pregenomic RNA was established with a 78.9% sensitivity and a 100% specificity. Multivariate logistic regression showed that serum HBcrAg-positive was associated with a high risk of HCC in OBI patients (adjusted odds ratio: 3.57, P = 0.037). Kaplan-Meier survival analysis showed that the cumulative recurrence rate at 84 months in the HBcrAg-positive group was higher than HBcrAg-negative one (50.0% vs 11.8%, hazard ratio = 4.995, P = 0.016).
CONCLUSION: HBcrAg is a promising serum marker for the diagnosis of OBI in HBsAg-negative population. HBcrAg is related to OBI-related HCC and is valuable in evaluating recurrence after radical resection surgery.
DESIGN AND METHODS: The OBI status was determined by nested polymerase chain reaction. HBcrAg and common HBV clinical indicators were compared between the OBI and non-OBI groups. A detection pathway based on HBcrAg was established for OBI diagnosis. HBsAg-negative patients (124 HCC and 53 non-HCC) were enrolled for risk assessment of HBcrAg in OBI-related HCC.
RESULTS: A detection pathway for diagnosing OBI based on HBcrAg combined with hypersensitive HBV DNA and pregenomic RNA was established with a 78.9% sensitivity and a 100% specificity. Multivariate logistic regression showed that serum HBcrAg-positive was associated with a high risk of HCC in OBI patients (adjusted odds ratio: 3.57, P = 0.037). Kaplan-Meier survival analysis showed that the cumulative recurrence rate at 84 months in the HBcrAg-positive group was higher than HBcrAg-negative one (50.0% vs 11.8%, hazard ratio = 4.995, P = 0.016).
CONCLUSION: HBcrAg is a promising serum marker for the diagnosis of OBI in HBsAg-negative population. HBcrAg is related to OBI-related HCC and is valuable in evaluating recurrence after radical resection surgery.